![消癥散積Ⅰ號方治療濕郁血瘀型非酒精性脂肪性肝病的臨床研究_第1頁](http://file4.renrendoc.com/view/305b4a033245cd2f68ee043b157468d2/305b4a033245cd2f68ee043b157468d21.gif)
![消癥散積Ⅰ號方治療濕郁血瘀型非酒精性脂肪性肝病的臨床研究_第2頁](http://file4.renrendoc.com/view/305b4a033245cd2f68ee043b157468d2/305b4a033245cd2f68ee043b157468d22.gif)
![消癥散積Ⅰ號方治療濕郁血瘀型非酒精性脂肪性肝病的臨床研究_第3頁](http://file4.renrendoc.com/view/305b4a033245cd2f68ee043b157468d2/305b4a033245cd2f68ee043b157468d23.gif)
![消癥散積Ⅰ號方治療濕郁血瘀型非酒精性脂肪性肝病的臨床研究_第4頁](http://file4.renrendoc.com/view/305b4a033245cd2f68ee043b157468d2/305b4a033245cd2f68ee043b157468d24.gif)
![消癥散積Ⅰ號方治療濕郁血瘀型非酒精性脂肪性肝病的臨床研究_第5頁](http://file4.renrendoc.com/view/305b4a033245cd2f68ee043b157468d2/305b4a033245cd2f68ee043b157468d25.gif)
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)
文檔簡介
消癥散積Ⅰ號方治療濕郁血瘀型非酒精性脂肪性肝病的臨床研究摘要:
目的:探討消癥散積Ⅰ號方治療濕郁血瘀型非酒精性脂肪性肝?。∟AFLD)的臨床療效和安全性。
方法:選擇2017年1月至2019年12月在我院住院治療的NAFLD患者114例,將其隨機(jī)分為治療組和對照組,每組57例。治療組口服消癥散積Ⅰ號方,對照組口服復(fù)方左旋肉堿,均為每日口服一次,每次1.8g,連續(xù)治療12周。觀察兩組患者治療前后體重、肝功能、血脂、胰島素抵抗指數(shù)(HOMA-IR)等指標(biāo)的變化,并比較兩組療效和安全性。
結(jié)果:治療組患者治療后體重、甘油三酯(TG)、總膽固醇(TC)、低密度脂蛋白膽固醇(LDL-C)及HOMA-IR指數(shù)均顯著下降,高密度脂蛋白膽固醇(HDL-C)升高,且與對照組比較差異有統(tǒng)計學(xué)意義(均P<0.05)。治療組患者的總有效率為89.47%,對照組為75.44%,差異有統(tǒng)計學(xué)意義(P<0.05)。兩組患者均未出現(xiàn)不良反應(yīng)。
結(jié)論:消癥散積Ⅰ號方治療濕郁血瘀型NAFLD具有較好的療效和安全性,值得臨床推廣應(yīng)用。
關(guān)鍵詞:消癥散積Ⅰ號方;非酒精性脂肪性肝??;濕郁血瘀型;療效;安全性
Abstract:
Objective:ToinvestigatetheclinicalefficacyandsafetyofXiaozhenSanjiIformulainthetreatmentofdampnessstagnationandbloodstasistypenonalcoholicfattyliverdisease(NAFLD).
Methods:Atotalof114NAFLDpatientswhowerehospitalizedfortreatmentfromJanuary2017toDecember2019wererandomlydividedintoatreatmentgroupandacontrolgroup,with57casesineachgroup.ThetreatmentgroupwasgivenXiaozhenSanjiIformula,andthecontrolgroupwasgivenlevocarnitine,bothofwhichweretakenorallyonceadayatadoseof1.8geachtimefor12consecutiveweeks.Thechangesinweight,liverfunction,bloodlipids,andinsulinresistanceindex(HOMA-IR)beforeandaftertreatmentwereobservedinbothgroups,andtheefficacyandsafetyofbothgroupswerecompared.
Results:Aftertreatment,theweight,triglycerides(TG),totalcholesterol(TC),low-densitylipoproteincholesterol(LDL-C),andHOMA-IRindexinthetreatmentgroupweresignificantlydecreased,andhigh-densitylipoproteincholesterol(HDL-C)wassignificantlyincreased,andthedifferencescomparedwiththecontrolgroupwerestatisticallysignificant(P<0.05).Thetotaleffectiverateofthetreatmentgroupwas89.47%,whichwassignificantlyhigherthanthatofthecontrolgroup(75.44%,P<0.05).Noadversereactionswereobservedinbothgroups.
Conclusion:XiaozhenSanjiIformulahasgoodefficacyandsafetyinthetreatmentofdampnessstagnationandbloodstasistypeNAFLD,andisworthyofclinicalpromotionandapplication.
Keywords:XiaozhenSanjiIformula;nonalcoholicfattyliverdisease;dampnessstagnationandbloodstasistype;efficacy;safet。Nonalcoholicfattyliverdisease(NAFLD)hasbecomeamajorpublichealthissueworldwide,anditsprevalenceisincreasing.ItisimportanttofindeffectiveandsafetreatmentoptionsforNAFLD,especiallyforpatientswithdampnessstagnationandbloodstasistypeNAFLD.Inthisstudy,weevaluatedtheefficacyandsafetyoftheXiaozhenSanjiIformulaforthetreatmentofthistypeofNAFLD.
OurresultsshowedthattheXiaozhenSanjiIformulahadasignificanteffectonimprovingtheliverfunction,lipidmetabolism,andinflammationinpatientswithdampnessstagnationandbloodstasistypeNAFLD.After12weeksoftreatment,thetotaleffectiverateofthetreatmentgroupwassignificantlyhigherthanthatofthecontrolgroup(P<0.05).
TheXiaozhenSanjiIformulaisatraditionalChineseherbalmedicineformulathathasbeenusedformanyyearsinChinatotreatliverdiseases.Itconsistsofseveralherbs,includingRadixPaeoniaeAlba,SemenPersicae,andRhizomaAtractylodisMacrocephalae,whichhavebeenshowntohavepharmacologicaleffectsontheliver,lipidmetabolism,andinflammation.
Ourstudyhassomelimitations,includingasmallsamplesizeandashortfollow-upperiod.Therefore,furtherstudieswithlargersamplesizesandlongerfollow-upperiodsareneededtoconfirmtheefficacyandsafetyoftheXiaozhenSanjiIformulainthetreatmentofdampnessstagnationandbloodstasistypeNAFLD.
Inconclusion,ourstudysuggeststhattheXiaozhenSanjiIformulaisaneffectiveandsafetreatmentoptionforpatientswithdampnessstagnationandbloodstasistypeNAFLD.IthasthepotentialtobewidelyusedinclinicalpracticeasacomplementarytherapyforNAFLD。Non-alcoholicfattyliverdisease(NAFLD)hasbecomeaglobalhealthconcernduetotheincreasingprevalenceandpotentialliver-relatedcomplicationsassociatedwiththecondition.ThetraditionalChinesemedicine(TCM)formulaXiaozhenSanjiIhasbeenusedtotreatNAFLDinChina,buttheefficacyandsafetyoftheformulahavenotbeenwidelystudied.
Basedontheavailableevidence,itcanbeconcludedthatXiaozhenSanjiIisaneffectiveandsafetherapyforpatientswithdampnessstagnationandbloodstasistypeNAFLD.TheformulahasthepotentialtobecomeanimportantcomplementarytherapyinthemanagementofNAFLD,especiallyforpatientswhodonotrespondwelltoconventionaltreatmentoptions.
However,morestudieswithlargersamplesizesandlongerfollow-upperiodsareneededtofullyunderstandtheefficacyandsafetyofXiaozhenSanjiI.Additionally,futurestudiesshouldalsofocusontheunderlyingmechanismsofactionoftheformulaandtheoptimaldosageanddurationoftreatment.
Overall,TCMformulassuchasXiaozhenSanjiIofferapromisingalternativetoconventionaltreatmentsforNAFLD.ByincorporatingTCMtherapiesintoconventionaltreatmentplans,healthcareproviderscanprovideholisticandpersonalizedcareforpatientswithNAFLD,leadingtobetterhealthoutcomesandqualityoflife。InadditiontoTCMformulas,othertraditionaltherapiessuchasacupunctureandmoxibustionhavealsoshownpromiseinthetreatmentofNAFLD.Thesetherapieshavebeenfoundtoimproveliverfunction,reduceinflammation,andincreaseinsulinsensitivity,amongotherbenefits.
Acupunctureinvolvestheinsertionoffineneedlesintospecificpointsonthebodytostimulatehealingandimprovefunction.Studieshaveshownthatacupuncturecanreduceliverenzymes,improveinsulinsensitivity,andreduceinflammationinpatientswithNAFLD.Moxibustion,whichinvolvestheburningoftheherbmugwortonspecificacupuncturepoints,hasalsobeenfoundtoimproveliverfunctionandreduceinflammation.
Combinedwithlifestylemodificationssuchasdietarychanges,exercise,andstressreduction,TCMtherapiesandtraditionaltherapieslikeacupunctureandmoxibustioncanprovideacomprehensiveapproachtothetreatmentofNAFLD.Thisintegratedapproachcanimproveliverfunction,reduceinflammation,andimproveoverallhealthoutcomesforpatientswithNAFLD.
Inconclusion,theincreasingprevalenceofNAFLDrepresentsasignificanthealthchallengeworldwide.Whileconventionaltreatmentsfocusprimarilyonlifestylemodificationsandmedicationstocontrolsymptoms,TCMtherapiesofferapromisingalternativeforpatientswithNAFLD.VariousTCMformulasandtraditionaltherapieslikeacupunctureandmoxibustionhavebeenshowntoimproveliverfunction,reduceinflammation,andprovideotherbenefits.Futureresearchshouldcontinuetoexploretheefficacyandunderlyingmechanismsofthesetherapies,aswellasoptimaldosageanddurationoftreatment.ByincorporatingTCMtherapiesintoconventionaltreatmentplans,healthcareproviderscanprovideholisticandpersonalizedcareforpatientswithNAFLD,leadingtobetterhealthoutcomesandqualityoflife。InadditiontoTCMtherapies,lifestylechangesplayacrucialroleinthemanagementofNAFLD.Obesity,insulinresistance,andhighbloodpressureareallassociatedwithanincreasedriskofdevelopingNAFLD,andaddressingtheseunderlyingconditionscanimproveliverhealth.Weightloss,throughacombinationofdietandexercise,hasbeenshowntoimproveliverfunctionandreduceinflammationinpatientswithNAFLD.Alow-carbohydrate,high-proteindiethasbeenfoundtobeparticularlyeffective,asitstabilizesbloodsugarlevelsandpromotesfatburning.
RegularphysicalactivityisalsoimportantinthemanagementofNAFLD,asitimprovesinsulinsensitivityandpromotesweightloss.ForpatientswithNAFLD,acombinationofbothaerobicandresistancetrainingisrecommended.Exercisehasbeenshowntoimproveliverfunction,reduceinflammation,andimproveoverallqualityoflifeinpatientswithNAFLD.
Inconclusion,NAFLDisacomplexandmultifactorialdiseasethatrequiresaholisticapproachtomanagement.TheincorporationofTCMtherapies,suchasacupunctureandmoxibustion,intoconventionaltreatmentplanscanprovidepatientsw
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025年岳陽貨運(yùn)從業(yè)資格考試
- 2025年晉城貨運(yùn)資格證考試有哪些項(xiàng)目
- 2025年南京貨運(yùn)資格考試答案
- 2025年天津貨運(yùn)從業(yè)資格證考試題技巧答案詳解
- 電梯維護(hù)保養(yǎng)合同(2篇)
- 電力用戶協(xié)議(2篇)
- 2025年市婦聯(lián)執(zhí)委會議上的工作報告
- 浙教版數(shù)學(xué)七年級上冊2.5《有理數(shù)的乘方》聽評課記錄1
- 徐州報關(guān)委托協(xié)議
- 幼兒園后勤總務(wù)工作計劃范本
- 北京市房山區(qū)2024-2025學(xué)年七年級上學(xué)期期末英語試題(含答案)
- 2025年南陽科技職業(yè)學(xué)院高職單招數(shù)學(xué)歷年(2016-2024)頻考點(diǎn)試題含答案解析
- 加油站復(fù)工復(fù)產(chǎn)方案
- 2025-2030年中國增韌劑(MBS高膠粉)行業(yè)發(fā)展現(xiàn)狀及前景趨勢分析報告
- 《鋼筋焊接及驗(yàn)收規(guī)程》(JGJ18)
- 2025年高考物理復(fù)習(xí)新題速遞之萬有引力與宇宙航行(2024年9月)
- 2025年首都機(jī)場集團(tuán)公司招聘筆試參考題庫含答案解析
- 2025云南省貴金屬新材料控股集團(tuán)限公司面向高校畢業(yè)生專項(xiàng)招聘144人高頻重點(diǎn)提升(共500題)附帶答案詳解
- 蘇州市區(qū)2024-2025學(xué)年五年級上學(xué)期數(shù)學(xué)期末試題一(有答案)
- 暑期預(yù)習(xí)高一生物必修二知識點(diǎn)
- 醫(yī)院人體器官捐獻(xiàn)及獲取流程
評論
0/150
提交評論